Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer

International Journal of Gynecological Cancer

Volumn 19, Issue 6, 2009, Pages 1029-1036

  Michelsen, Trond M ^a,e   Dørum, Anne ^b,c   Tropé, Claes G ^c,d   Fossa, Sophie D ^c,d   Dahl, Alv A ^c,d  

^a SLrlandet Hospital   (Sweden)

^b National Resource Centre for Women's Health   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e SLrlandet Hospital   (Norway)

Author keywords

BRCA1 2 mutations; Fatigue; Ovarian cancer; Quality of life; Risk reducing salpingo oophorectomy

Indexed keywords

ANALGESIC AGENT; ANTIHYPERTENSIVE AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; PSYCHOTROPIC AGENT;

ADULT; ANXIETY; ARTICLE; BODY IMAGE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DEPRESSION; FAMILIAL CANCER; FATIGUE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MORBIDITY; NORWAY; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RISK REDUCTION; SALPINGOOOPHORECTOMY;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FATIGUE; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MUTATION; NORWAY; OVARIAN NEOPLASMS; OVARIECTOMY; POSTOPERATIVE COMPLICATIONS; QUALITY OF LIFE; QUESTIONNAIRES; RISK FACTORS; RISK REDUCTION BEHAVIOR; SALPINGOSTOMY;

EID: 70349230914     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a83cd5     Document Type: Article

References (30)

1. Domchek SM, Rebbeck TR. Prophylactic oophorectomy in women at increased cancer risk. Curr Opin Obstet Gynecol. 2007;19:27-30.
2. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329-1333.
3. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK, eds. SEER Cancer Statistics Review, 1973Y1999. Bethesda, MD: National Cancer Institute; 2002. Available at: http://seer.cancer.gov/Publications/CSR1973- 1999/.
4. The Norwegian Cancer Society, Annual report, 2006. Available at: www.kreftforeningen.no, 080508.
5. Pavelka JC, Karlan BY. Hereditary ovarian cancerVassessing risk and prevention strategies. Obstet Gynecol Clin North Am. 2007;34:651-665.
6. Bemejo-Pérez MJ, Márquez-Calderón S, Llanos-Méndez A. Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer. 2007;121:225-231.
7. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26:1331-1337.
8. Narod S, Lubinski J, Ghadirian P, et al. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carries: a case-control study. Lancet Oncol. 2006;7:402-406.
9. Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nat Clin Pract Oncol. 2007;4:578-590.
10. Madalinska JB, Hollenstein J, Bleiker E, et al. Quality-of life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol. 2005;23:6890-6898.
11. Elit L, Esplen MJ, Butler K, et al. Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Fam Cancer. 2001;1:149-156.
12. Robson M, Hensley M, Barakat R, et al. Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol. 2003;89:281-287.
13. Hassa H, Tanir HM, Yildirim A, et al. Associated factors with urogenital score in natural and surgical menopause. Maturitas. 2005;52:65-69.
14. Hilditch JR, Lewis J, Peter A, et al. A menopause- specific quality of life questionnaire: development and psychometric properties. Maturitas. 1996;24:161-175.
15. Loge JH, Ekeberg O, Kaasa S. Fatigue in the general Norwegian population: Normative data and associations.J Psychosom Res. 1998;45:53Y65. (Pubitemid 28339940)
16. Liu J, Eden JA. The menopausal experience of Greek women living in Sydney. Menopause. 2008;15:476-481.
17. Geirdal AK, Reichelt JG, Dahl AA, et al. Mental distress in women at risk for hereditary breast/ovarian or HNPCC cancers in the absence of demonstrated mutations. Fam Cancer. 2005;4:121-126.
18. Thorsen L, Nystad W, Stigum H, et al. The association between self-reported physical activity and prevalence of depression and anxiety in long-term survivors of testicular cancer and in general population sample. Support Care Cancer. 2005;13:637-646.
19. Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. J Psychosom Res. 1993;37:147-153.
20. Bjelland I, Dahl AA, Tangen T, et al. The validity of the Hospital Anxiety and Depression Scale. J Psychosom Res. 2002;52:69-77.
21. Mykletun A, Stordal E, Dahl AA. The Hospital Anxiety and Depression Scale (HADS): factor structure, item analyses, and internal consistency in a large population. Br J Psychiatry. 2001;179:340-344.
22. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
23. Hopwood P, Fletcher I, Lee A, et al. A body image scale for use with cancer patients. Eur J Cancer. 2001;37:189-197.
24. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
25. Lipsey MW, Wilson DB. Practical Meta-analysis. Thousand Oaks, CA: Sage; 2001.
26. Bower JE, Ganz PA, Desmond KA, et al. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol. 2000;18:743-753.
27. Schwartz CE, Andresen EM, Nosek MA, et al. Response shift theory: important implications for measuring quality of life in people with disability. Arch Phys Med Rehabil. 2007;88:529-536.
28. Madalinska JB, van Beurden M, Bleiker EM, et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol. 2006;24:3576-3582.
29. Stigum H, Magnus P, Veierod M, et al. Impact on sexually transmitted disease spread of increased condom use by young females, 1987-92. Int J Epidemiol. 1995;24:813-820.
30. Stigum H, Magnus P, Harris JR, et al. Frequency of sexual partner change in a Norwegian population. Data distribution and covariates. Am J Epidemiol. 1997;145:636-643.